Document is current

Article History

Received: 21 July 2021

Accepted: 16 September 2021

First Online: 28 September 2021

Declarations

:

: JTH, GDB, ZM, JR, and AN are employees of Supernus Pharmaceuticals, Inc. SVF received income, potential income, travel expenses continuing education support and/or research support in the past year from: Takeda, OnDosis, Tris, Otsuka, Arbor, Ironshore, Rhodes, Akili Interactive Labs, Enzymotec, Sunovion, Supernus, and Genomind. With his institution, he has US patent US20130217707 A1 for the use of sodium-hydrogen exchange inhibitors in the treatment of ADHD. He also receives royalties from books published by Guilford Press: <i>Straight Talk about Your Child’s Mental Health</i>; Oxford University Press: <i>Schizophrenia: The Facts</i>; and Elsevier: <i>ADHD: Non-Pharmacologic Interventions</i>. He is Program Director of . RG was a paid consultant to Ironshore Pharmaceuticals, Sunovion Pharmaceuticals, Supernus Pharmaceuticals, Teva, Biomedical Science Institutes, Nanomi BVs, Laboratorios Liconsa, Massachusetts General Hospital, UCB, Recordati Rare Diseases, Indivior, Tris Pharma, and F. Hoffmann-La Roche.

: This is a post hoc analysis of integrated data from four clinical studies. In each study, informed consent/assent forms were signed as applicable. Each study protocol was approved by Advarra Institutional Review Board (IRB) and conducted in accordance with the Helsinki Declaration and the International Council for Harmonisation Note for Guidance on Good Clinical Practice. All versions of the informed consent/assent form were reviewed and approved by the IRB.